This is a preview of subscription content, log in via an institution to check access.
Reference
Gandjour A, et al. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany. Applied Health Economics and Health Policy : 7 Nov 2019. Available from: URL: http://doi.org/10.1007/s40258-019-00523-1
Rights and permissions
About this article
Cite this article
Secukinumab cost effective for active psoriatic arthritis. PharmacoEcon Outcomes News 842, 28 (2019). https://doi.org/10.1007/s40274-019-6420-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6420-6